Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

ETF What's Up

You may unsubscribe at any time by clicking the “unsubscribe” link within the emailed newsletter. By signing up, you agree to our Privacy Policy and Terms and Conditions.

BBP

Virtus LifeSci Biotech Products ETF

The BBP Exchange Traded Fund (ETF) is provided by VIRTUS Investment Partners. It is built to track an index: LifeSci Biotechnology Products Index. The BBP ETF provides physical exposure, so by buying it you actually own parts of all the 66 underlying holdings. This share class generates a stream of income by distributing dividends.

Advertisement

Advertisement

$103.46
-$0.014 (-0.01%) 2 days ago
1:30 PM 09/11/26 Closed
1D price range
$103.45$104.51
52W price range
$68.05$110.05
YTD Perf.
+29.59%
YTD Flows
Annualized volatility
Fund AuM
€107M
Share class AuM
€107M
TTM Yield
Tracking Error
Tracking Difference
ISIN
US26923G2021
TER
0.34%
Inception date
12/16/2014
Replication method
Dividend policy
Compare similar ETFs
API
PerformanceDec 31, 2025 - Sep 11, 2026
0%10%20%30%40%JANMARMAYJULSEP
Flows
Join for free to unlock
Data as of 07/31/26
Healthcare
98.20%
Unavailable
1.80%
Latest BBP news

No content available for this fund

FAQ about BBP

BBP is a Passive ETF. This ETF provides exposure to Equally Weighted US Equities.
BBP tracks the LifeSci Biotechnology Products Total Return Index - USD, through a full replication replication method.
BBP carries a total expense ratio (TER) of 0.34%, indicating the annual cost for holding the fund.
BBP was introduced to the market on December 16, 2014. It trades on United States
Virtus LifeSci Biotech Products ETF, BBP, is provided by VIRTUS Investment Partners. Learn more about VIRTUS Investment Partners here.
BBP oversees €107M in assets as of September 11, 2026.
BBP follows a distributing dividend policy, meaning it pays out income to investors.
As of July 31, 2026, BBP has significant geographic allocations in USA, United Kingdom and Switzerland.
As of July 31, 2026, BBP focuses largely on Healthcare.
As of July 31, 2026, BBP holds 66 positions in its portfolio, with 26.78% of assets concentrated in its top 15 holdings.
As of July 31, 2026, BBP top three holdings include Crinetics Pharmaceuticals, Inc., Verastem, Inc. and Nuvation Bio, Inc..
The base currency of BBP is USD.
Data as of 07/31/26
Crinetics Pharmaceuticals, Inc.
3.24%
Verastem, Inc.
1.98%
Nuvation Bio, Inc.
1.80%
Omeros Corp.
1.73%
Geron Corp.
1.72%
BridgeBio Pharma, Inc.
1.68%
Agios Pharmaceuticals, Inc.
1.67%
Protagonist Therapeutics, Inc.
1.65%
BeOne Medicines Ltd.
1.64%
Kiniksa Pharmaceuticals International Plc
1.63%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight